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LETTER TO THE EDITOR
Meta-analysis of chemotherapy in head and neck cancer: reply to the
letter from JP Pignon et al
Sir - I would like to thank Dr Pignon and colleagues at the
MACH-NC for their helpful and encouraging response to the
recently published meta-analysis of chemotherapy trials in
head and neck cancer (Munro, 1995), and also for providing
me with a copy of their protocol. I am also grateful for being
given the opportunity to reply to some of the points they
raise in their letter.
I confined my attention to trials published before August
1993; the MACH-NC group include trials still accruing
patients in December 1993. This has an obvious impact on
the number of trials that would be considered eligible for
analysis. The lag between accrual and publication could
easily explain why the MACH-NC group was able to identify
20-25 more trials than were included in my study. The
comparison of patient numbers between the two overviews is
shown in Table I.
Trial identification and bias are inevitable problems in any
meta-analysis. The sensitivity analyses in the original publica-
tion show that failure to include the trials identified by the
MACH-NC group would be unlikely to affect the overall
conclusion. There are interesting parallels with the recent
meta-analyses on the role of thoracic irradiation in small-cell
lung cancer. The conclusions from the literature-based
analysis ofWarde and Payne (1992) were in broad agreement
with those from the per-patient analysis of Pignon et al.
(1992) (Table II).
The information content of a clinical trial will depend
upon the number of comparisons made. A three-arm trial
makes two comparisons; if there is a control arm and two
experimental arms then the control group is, effectively, used
twice. In assembling data for a meta-analysis it seems
reasonable to count such a trial as two comparisons rather
than as a single trial.
The point on survival time is well taken. I plead guilty: in
a literature-based analysis you have to take what you are
given.
Table I
Comparison MACH-NC Munro Munro as %
Any chemotherapy 9186 7443 81%
Neoadjuvant 4786 4141 87%
Concurrent 3335 2850 85%
I think that it is legitimate to include so-called 'organ-
conserving' studies in a meta-analysis, providing they fulfil
the criteria for acceptance. The primary aim of a study
should not be confused with the information it might pro-
vide. A trial of treatment designed to improve local control
might, unexpectedly, show decreased survival in the treated
arm. The data on survival cannot then be ignored simply
because they are not in accord with the original intention of
the investigators.
I apologise for the error in Table I: the Lo trial (ref. 25)
was a subset of patients from the Gollin trial (ref. 12); in
Table I eligibility for ref. 25 should have read 'subset of 0
Op from below updated'. In fact, the best way to deal with
this trial is simply to use the overall updated data, including
all patients originally randomised (n = 151), from Lo et al.
Handling the data in this way does not affect the conclusion.
The heterogeneity of head and neck cancer presents major
problems for a literature-based analysis. There are many
different primary sites, different TNM categories, differences
in patient-related criteria for study entry, differences in
chemotherapy regimens, and so many possible permutations,
that to talk of 'chemotherapy for head and neck cancer' is
only a little more specific than talking of food for animals.
Everything is in there, from hay for horses to wildebeest for
lions. The major strength of the per-patient analysis will be,
through a knowledge of prognostic factors for individual
patients, the ability to identify those subgroups of patients
for whom particular forms of chemotherapy might be partic-
ularly beneficial.
In an imperfect world we must often make do with
imperfect information. The literature-based meta-analysis is a
moderately useful technique, but it can never provide the
power, sophistication and detail that come from an analysis
based on data from individual patients. The MACH-NC are
to be congratulated upon their vision and tenacity.
Yours etc,
AJ Munro
Department of Radiotherapy
St Bartholomew's Hospital
West Smithfield
London EClA 7BE
UK
Table II
OR for death Absolute difference
Study No. of trials No. ofpatients (95% CI) in 2 year survival
Warde and 11 1911 0.65 (0.57 to 5.4%
Payne (1992) 0.77)
Pignon et al. 13 2140 0.86 (0.78 to 5.5%
(1992) 0.94)
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